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Purpose: Heart failure (HF) is a chronic, frequent and disabling condition but with a
modifiable course and a large potential for improving. The aim of this study was to validate
the two available clinical prediction rules for mortality at one year in patients with primo-
hospitalization for decompensated HF: PREDICE and AHEAD. The secondary aim was to
evaluate in our setting the changes in the clinical pattern of HF in the last decade in patients
hospitalized for a first episode of the disease.
Patients and methods: A prospective multicenter cohort study, which included 180
patients hospitalized with “de novo” HF was conducted to validate the PREDICE score.
Calibration and discrimination measurements were calculated for the PREDICE model and
the PREDICE score (using the validation cohort of the PREDICE) and the AHEAD score
(using both the development and the validation cohort of the PREDICE).
Results: For the PREDICE models, the area under the curve (AUC) was 0.68 (95% confidence
interval [CI]: 0.57–0.79) and the calibration slope 0.65 (95% CI: 0.21–1.20). For the PREDICE
score AUCwas 0.59 (95%CI: 0.47–0.71) and slope 0.42 (95%CI: −0.20–1.17). For theAHEAD
score the AUCwas 0.68 (95%CI: 0.62–0.73) and slope 1.38 (95% CI: 0.62–0.73) when used the
development cohort of PREDICE and the AUC was 0.58 (95% CI: 0.49–0.67), and slope 0.68
(95% CI: −0.06 to 1.47) when used its validation cohort.
Conclusion: The present study shows that the two risk scores available for patients with
primo-hospitalization for decompensated HF (PREDICE and AHEAD) are not currently
valid for predicting mortality at one-year. In our setting the clinical spectrum of hospitalized
patients with new-onset HF has been modified over time. The study underscores the need to
validate the prognostic models before clinical implementation.
Keywords: heart failure, validation studies as topics, severity of illness index, inpatients
Introduction
Heart failure (HF) is a heterogeneous clinical prevalent syndrome.1 Its prevalence
increases as patients age.2,3 Furthermore, HF is one of the leading causes of death in
developed countries, accounting for 17,000 deaths in Spain in 2014 and it repre-
sents a high economic burden in Spain and the rest of the world.3–5
Predicting the clinical outcomes of heart failure patients may be useful for
decision-making in terms of resources and clinical management of the disease.
Prognostic models and clinical prediction rules or scores are tools aimed at helping
clinicians assess the risk-benefit balance, so they can make better choices.6,7 In the
care for HF patients, invasive diagnostic tests and potentially severely harmful
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treatments are available, so assessing risk-benefit balance
is challenging. At present, more than one hundred prog-
nostic models exist in HF. Their prediction ability is mod-
erate to poor,1,8–10 yet there are few variables that are
consistently kept in some of the models.9,11
In 2012, no prognostic model was available to be used
in hospitalized patients with newly diagnosed acute HF, so
our group developed a one-year prognostic model and
clinical prediction score with the aim of being useful at
patients’ bedsides, this is the PREDICE-score.12 Since
then, only one other risk model (AHEAD-score) has
been reported to predict mortality in hospitalized patients
with acute HF.13
Despite the prediction ability of prognostic models in
HF not being perfect, it has a potential role to be helpful
for clinicians. However, a lack of external validation com-
promises its validity.14 Therefore, developed models
should be externally validated or calibrated so clinicians
can make proper use of them.15
The primary aim of this study was to validate the two
available clinical prediction rules for mortality at one year
in patients with primo-hospitalization for decompensated
HF: PREDICE and AHEAD. The secondary aim was to
evaluate, in our setting, the changes in the clinical pattern
of HF in the last decade in patients hospitalized after a first
episode of the disease.
Materials and methods
A prospective multicenter cohort study was designed for
external validation of the PREDICE-score. A total of 180
patients hospitalized with a first episode (“de novo”) of HF
between 2013 and 2015 in three Spanish hospitals (60
patients for each of the centers) of the National Health
Service (12 de Octubre University Hospital, Madrid;
Virgen del Rocio University Hospital, Seville; and Valme
University Hospital, Seville) were included correlatively to
complete the calculated sample size for an estimated mortal-
ity at one year of 16% (according to 2013 local data), using
5% precision with a 95% confidence interval (CI). The first
two centers provided advanced medical care and the last one
(Valme University Hospital), standard medical care. The
inclusion criteria were: patient hospitalized at the study cen-
ter with a primary diagnosis of HF (following Framingham
criteria), over 18-year-old, resident in the area of reference of
the study center. The exclusion criteria were previous diag-
nosis of HF, diagnosis of HF not displayed at discharge report
and patients not residing in the hospital area. The patients
were followed up at one year after discharge. Development12
and validation PREDICE datasets were used to externally
validate the AHEAD-score.13
Outcomes
The outcome of interest was mortality from any cause at
one year after discharge. Mortality predictions at 3, 5 and
7.5 years for the AHEAD-score13 were not validated since
this information was not available in datasets.
Validation
To validate the model and score, we use calibration and
discrimination. It adds global performance measures.
Calibration reflects the extent to which the predicted prob-
abilities and actual probabilities agree. We focus on the
calibration-in-the-large (intercept) plus the calibration
slope. The concordance statistic (c-statistic) represents
the probability that individuals with the outcome will
receive a higher predicted probability than those without
it. It corresponds to the area under the curve (AUC) and
their 95% CI.16,17 The missing data were excluded from
the sample and no method of data input was performed.
The variables included in the PREDICE-score valida-
tion are: age, eGFR, serum sodium levels, dependency for
daily basic activities and physiopathology diagnosis (sys-
tolic function preserved or reduced).12
The formula that was constructed in the PREDICE
derivation article12 is called the prognostic index (PI):7
The risk of mortality at one year for the PREDICE
model12 were calculated using PI, where the estimated
glomerular filtration rate (eGFR) was estimated with the
4-variable version of the Modification of Diet in Renal
Disease equation (MDRD4).18 Age, eGFR, serum sodium
levels, dependency for daily basic activities and physio-
pathology diagnosis (systolic function preserved or
reduced) were used to predict the one-year death risk
using the clinical prediction rule PREDICE-score.12
The probabilities of mortality at one-year for the
AHEAD-score were estimated using atrial fibrillation,
creatinine levels, hemoglobin levels, age and the existence
of diabetes mellitus.13 The original formula was requested
from the correspondence author. Because the exact for-
mula was not provided, the score was firstly obtained and
then, probability was assigned using the AHEAD-score
table.13
The distribution of characteristics of development and
validation samples were compared separately. Additionally,
relatedness between validation and development PREDICE
samples was quantified using the c-statistic.16 The predictive
Ruiz-Ruiz et al Dovepress
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ability of the models was evaluated based on calibration and
discrimination.
Ethical aspects
The study was conducted in accordance with the
Declaration of Helsinki and followed the rules of security
and privacy. The Project was approved by the ethical
committees of the three participating hospitals (protocol
reference: 06/117). According to Spanish law, patient con-
sent is not required for register-based studies. No further




The baseline characteristics and outcome of the different
PREDICE and AHEAD populations are presented in Table 1.
First, the PREDICE derivation cohort was compared
with the PREDICE validation cohort. Patients in the vali-
dation cohort were slightly older (median age, 73.6 vs
75 years), had a slower rate of eGFR (median clearance,
38.6 vs 30.7 ml/min/1.73 m2), had a higher rate of systolic
dysfunction (23.9% vs 37%), had similar serum sodium
levels (median, 138.1 vs 138.5 mEq/l) and they had similar
levels of independence in basic daily activities (89.9% vs
88.9%). Mortality at one year was 16.3% in the derivation
cohort and 22.5% in the validation cohort. The concor-
dance statistic between the development and validation
PREDICE dataset (predictor variables and outcome status)
was 0.83 (95% CI, 0.79–0.86). The heterogeneity between
datasets was due to age and systolic dysfunction (0.77).
The characteristics of the PREDICE validation cohort
according to the primary outcome (mortality at one year)
are detailed in Table 2.
In relation to AHEAD, the derivation cohort of the
AHEAD-score was the Acute Heart Failure Database
(AHEAD) Network registry that included 6242 primo
hospitalizations for acute HF in the Czech Republic
between 2012 and 2016. The validation cohort of the
AHEAD-score was the GREAT registry that includes
6315 primo hospitalizations for acute HF from nine
cohorts of different countries during the same study
period.13 The validation and development PREDICE data-
sets were similar to the validation and development data-
sets of the AHEAD study in most of the baseline
characteristics and therapeutic management (Table 1).
However, PREDICE populations had a lower rate of
ischemic heart disease and the one-year mortality rates of
the AHEAD and GREAT cohorts (13.7% vs 14.4%,
respectively) were lower than those found in the derivation
and validation cohorts of the PREDICE study (16.6 and
22.5%, respectively).
Model evaluation - PREDICE
The discrimination of the PREDICE model in the valida-
tion dataset was 0.68 (95% CI 0.57–0.79). The calibration
intercept was 0.33 (95% CI −0.77 to 1.45) and the calibra-
tion slope was 0.65 (95% CI 0.21–1.20). The calibration
plot is shown in Figure 1.
Clinical prediction rule evaluation –
PREDICE-score
When we tested the clinical prediction rule, AUC was 0.59
(95% CI 0.47–0.71), the intercept −0.25 (95% CI −1.70 to
0.94) and the slope 0.42 (95% CI −0.20 to 1.17). Figure 2
shows its calibration.
Clinical prediction rule evaluation –AHEAD
(using development cohort of PREDICE)
When we used development cohort of PREDICE, the
AUC of AHEAD-score was 0.68 (95% CI 0.62–0.73),
the intercept −0.60 (95% CI −1.02 to −0.23) and the
slope 1.38 (95% CI 0.90–1.90). The calibration plot is
shown in Figure 3.
Clinical prediction rule evaluation - AHEAD
(using validation cohort of PREDICE)
We evaluated the model of the AHEAD-score also using
the validation cohort of PREDICE. It has an AUC of 0.58
(95% CI 0.49–0.67), an intercept of −0.78 (95% CI −1.39
to −0.24) and a slope of 0.68 (95% CI −0.06 to 1.47). The
calibration plot it is shown in Figure 4.
Discussion
Main findings
Our main results are that the performance of the model and
the clinical prediction rule are worse in the validation cohort
than in the development cohort. We have not been able to
validate the PREDICE-score or AHEAD-score. In addition,
high mortality and comorbidity of patients was found in the
validation PREDICE-cohort. The PREDICE-model showed
an acceptable discrimination with low calibration. The
AHEAD-SCORE exhibited similar discrimination to devel-
opment of the AHEAD study, but poor calibration.
Dovepress Ruiz-Ruiz et al
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Mathematical model - PREDICE
In the development cohort, the AUC of the mathematical
model was 0.76 while when we used validation cohort for
validation the AUC is 0.68. The values of the AUC operate
between 0.5 (no discrimination; it is considered to predict just
as chance) and 1.0 (perfect discrimination).16,19,20 As
expected, the performance of the model is worse in the valida-
tion cohort than in the development cohort. However, in both
populations the lower CI does not contain 0.5; suggesting that
discrimination is acceptable in both populations. By definition,
the intercept is always optimal (0) in the development sample.
Consequently, it is a useful statistic for identifying whether
unexplained differences exist in the outcome frequency of the
validation sample. Values below (or above) indicate that the
model overestimates (or respectively underestimates) the
outcome.16,21,22 The value of the intercept in the mathematical
model is 0.33, which overestimates the risk, but it works
thanks to its confidence interval (results above). The calibra-
tion slope can be used as a statistic for evaluating to what
extent the model’s predictive mechanisms remain valid in the
validation sample. Slope>1 occurs when predicted probabil-
ities do not vary enough (eg, predicted risks are systematically
too low) and 0<slope<1 occurs when they vary too much
(predicted risks are too low for low outcome risks and too
high for high outcome risks).19,23,24 The slope in the mathe-
matical model is 0.65, which is poor calibration.
Clinical prediction rule - PREDICE
The AUC of the clinical prediction rule is 0.59.
Discrimination is worse in the validation cohort (see
above). In the calibration, the intercept is −0.25 and its CI
does not contain 1. In addition, the slope is lower than 1.
This means poor calibration.
In summary, we have been able to validate the
model PREDICE-score. Conversely we have not been
able to validate the clinical prediction rule PREDICE.
We cannot reject the null hypothesis (model predicts
better than chance).














Age [years], mean (± SD) 73.6 (±12.3) 75 (±9.7) 0.16 74 77
Gender [female], n (%) 305 (50.8) 88 (48.9) 0.64 2536 (43.4) 2813 (44.5) 0,20
Ischemic cardiopathy, n (%) 98 (16.3) 18 (10.1) 0.04 1422 (24.3) 2255 (35.7) <0.001
Atrial fibrillation, n (%) 177 (29.5) 56 (31.1) 0.67 1792 (30.7) 2462 (39) <0.001
Valvulopathy, n (%) 160 (26.7) 23 (15) <0.001
HFrEF, n (%) 106 (23.9) 54 (37) <0.001
Hemoglobin [g/l], mean (± SD) 12.8 (±2.3) 12.3 (±2.2) 0.01 132 124
Sodium [mEq/l], mean (± SD) 138.1 (±4.6) 138.5 (±5) 0.32
Potassium [mEq/l], mean (± SD) 4.3 (±0.7) 4.4 (±0.7) 0.09
eGFR [ml/min], mean (± SD) 73.5 (±38.6) 72.0 (±30.7) 0.63
Beta-blockers, n (%) 188 (31.3) 90 (50.6) <0.001 2931 (52) 2129 (36) <0.001
ACE inhibitors, n (%) 328 (54.7) 96 (53.9) 0.75 3327 (59.3) 3357 (56.3) <0.001
ARBs, n (%) 104 (17.3) 27 (15.3) 0.46 1276 (23) 635 (18) <0.001
Diuretics, n (%) 439 (73.2) 137 (77) 0.43
Nitrates, n (%) 70 (11.7) 8 (4.9) 0.005
Digoxin, n (%) 152 (25.3) 26 (14.6) 0.002
Statins, n (%) 150 (25) 86 (48.3) <0.001
Antiaggregants, n (%) 263 (43.8) 83 (46.6) 0.59
Oral anticoagulants, n (%) 203 (33.8) 75 (42.1) 0.05
IBDA, n (%) 537 (89.5) 160 (88.9) 0.82
Charlson Index >2 points, n (%) 77 (12.8) 162 (90) <0.001
One-year mortality, n (%) 98 (16.3) 40 (22.5) 0.07 800 (13.7) 909 (14.4)
Notes: *GREAT registry. eGFR was estimated with the 4-variable version of the Modification of Diet in Renal Disease equation.
Abbreviations: SD, standard deviation; HFrEF, heart failure with reduced ejection fraction; eGFR, estimated glomerular filtration rate; ACE, angiotensin-converting-
enzyme; ARBs, angiotensin-II receptor blockers; IBDA, independent basic daily activities.
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Table 2 Baseline characteristics of the PREDICE validation cohort according one-year mortality
Overall [N=180] Death [N=40] Non death [N=140]
Age [years], mean (± SD) 75 (±9.7) 79.9 (±7.8) 73.7 (±9.9)
Gender [female], n (%) 88 (48.9) 17 (42.5) 71 (51.4)
Ischemic cardiopathy, n (%) 18 (10.1) 3 (7.5) 14 (10.2)
Atrial fibrillation, n (%) 56 (31.1) 18 (45) 38 (27.5)
Valvulopathy, n (%) 23 (15) 6 (18.2) 17 (14.4)
HFrEF, n (%) 54 (37) 14 (38.9) 40 (37)
Hemoglobin [g/l], mean (± SD) 12.3 (±2.2) 12.4 (±2.1) 12.3 (±2.2)
Sodium [mEq/l], mean (± SD) 138.5 (±5.0) 137.5 (±6.6) 138.9 (±4.4)
Potassium [mEq/l], mean (± SD) 4.4 (±0.7) 4.6 (±0.8) 4.4 (±0.6)
eGFR, [ml/min], mean (± SD) 72.0 (±30.7) 72.3 (±35.7) 70.8 (±27.9)
Beta-blockers, n (%) 90 (50.6) 14 (36.8) 75 (54.3)
ACE inhibitors, n (%) 96 (53.9) 19 (50) 75 (54.3)
ARBs, n (%) 27 (15.3) 6 (15.8) 20 (14.6)
Diuretics, n (%) 137 (77) 32 (84.2) 103 (74.6)
Nitrates, n (%) 8 (4.9) 5 (13.2) 2 (1.4)
Digoxin, n (%) 26 (14.6) 7 (18.4) 19 (13.8)
Statins, n (%) 86 (48.3) 15 (39.5) 69 (50)
Antiagregants, n (%) 83 (46.6) 17 (44.7) 64 (46.4)
Oral anticoagulants, n (%) 75 (42.1) 20 (52.6) 55 (39.9)
IBDA, n (%) 160 (88.9) 28 (70) 130 (94.2)
Charlson Index >2 points, n (%) 162 (90) 40 (100) 122 (87.1)
Note: eGFR was estimated with the 4-variable version of the Modification of Diet in Renal Disease equation.
Abbreviations: SD, standard deviation; HFrEF, heart failure with reduced ejection fraction; eGFR, estimated glomerular filtration rate; ACE, angiotensin-converting-
enzyme; ARBs, angiotensin-II receptor blockers; IBDA, independent basic daily activities.
Figure 1 Model calibration – PREDICE.
Notes: Calibration plot: predicted outcome probabilities (on the x-axis) plotted against observed outcome frequencies (on the y-axis). Perfect predictions should be on the 45° line.
Dovepress Ruiz-Ruiz et al
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Clinical prediction rule - AHEAD
Additionally, we tested the AHEAD-score, although target
populations are different. In the AHEAD-score we
included patients with primo-hospitalizations for HF,13
but not only “de novo” HF. Figures 1 and 3 show that
the PREDICE model underestimates the risk of mortality
while the PREDICE-score underestimates the real risk of
mortality. We see that the AHEAD-score overestimates the
risk too. We have verified that the calibration in the
AHEAD-score (using development and validation cohorts
Figure 2 SCORE calibration – PREDICE.
Notes: Calibration plot: predicted outcome probabilities (on the x-axis) plotted against observed outcome frequencies (on the y-axis). Perfect predictions should be on the 45° line.
Figure 3 SCORE calibration – AHEAD (using the development cohort of PREDICE).
Notes: Calibration plot: predicted outcome probabilities (on the x-axis) plotted against observed outcome frequencies (on the y-axis). Perfect predictions should be on the 45° line.
Ruiz-Ruiz et al Dovepress
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of PREDICE) is good but the discrimination in the
AHEAD-score is poor.
Differences between populations of the
PREDICE study
There are important differences between samples. On the
one hand, this penalizes the model because it is examined
on a sample with difference characteristics. But on the
other hand, if one model wants to be useful in clinical
practice it has to behave appropriately in any situation.
This increases the pragmatic value of the study.25
If we focus on variables include in the PREDICE-
score, we can find some differences.
Age has an influence on the prognosis. Furthermore,
old patients have an increased prevalence of comorbidities
and higher dependency. Advanced age is included in sev-
eral prognostic models for mortality after hospitalization
as in the PREDICE-score.13,26 However, both PREDICE
cohorts have similar mean age.
In several previous studies, social factors (living alone,
family support, follow-up medical visits, etc.) had been
proposed as predictors of mortality in chronic diseases, but
dependence had never been identified as an important
predictor.8,27,28 In the original paper, we underlined that
being dependent for daily basic activities was found to be
a relevant non-biological prognostic factor.12
The ejection fraction divides patients with HF into two
large groups: HF preserved and HF reduced. Both diseases are
very different in terms of etiology, prognosis and treatment.1,29
There may also be differences in the pathophysiological diag-
nosis, despite the similarity between both populations. In the
development cohort we did not obtain a pathophysiological
diagnosis in an important proportion of cases,12 which limits
the comparison with the validation cohort.
Additionally if the Charlson-Index (CIN) is used to mea-
sure comorbidities,30 we see that there is an important differ-
ence between both populations (p<0.001, Table 1). A
Charlson-score above 2 indicates the presence of multiple
comorbidities and/or advanced age, which generates worse
life expectancy in the following decade.30 In the PREDICE
validation cohort, we identify that 90% of patients have a
Charlson-Index higher than 2 points. However, in PREDICE
derivation cohort only 12.8% of patients have a CIN higher
than 2 points. These differences between both populations
explain that patients who are currently hospitalized are more
complex and that it is expected that they will have higher
mortality. Lastly, the use of beta-blockers was higher in the
validation cohort.
Figure 4 SCORE calibration – AHEAD (using the validation cohort of PREDICE).
Notes: Calibration plot: predicted outcome probabilities (on the x-axis) plotted against observed outcome frequencies (on the y-axis). Perfect predictions should be on the 45° line.
Dovepress Ruiz-Ruiz et al
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In summary, we found that patients belonging to the
validation cohort have high comorbidity and more fre-
quent systolic disfunction. These findings reveal that clin-
ical spectrum of hospitalized patients with HF has been
modified in the last decade. Additionally, there is a ten-
dency to hospitalize more severe patients which, despite
the better adherence to pharmacological treatment,
involves an increase of overall mortality in the hospital
setting.
Differences between the PREDICE and
AHEAD populations
Age, gender, ischemic cardiopathy, atrial fibrillation,
hemoglobin, beta-blockers, angiotensin converting enzyme
(ACE) inhibitors and angiotensin receptors blockers
(ARB) were the only data available for the four popula-
tions (Table 1). The most important differences between
the four populations are found in the use of beta-blockers
and in ischemic cardiopathy. Its prevalence is 35% in
GREAT, 24% in AHEAD, 16% in the PREDICE develop-
ment cohort and 10% in the PREDICE validation cohort.
Strengths and limitations of PREDICE
A strength of PREDICE is that the model includes a
limited number of non-invasive and widely available vari-
ables. Generally, in predictive models there is a conflict
between the complexity of the models and their clinical
applicability. Models should be easy and quick to use,
which should promote their use in normal clinical
practice.31,32 An example is Seattle Heart Failure, which
is a predictive model of survival in chronic HF.33 This
model is widely used but has more than twenty variables
so it is impossible to calculate it manually. For this reason,
Levy et al provide a calculator to facilitate the use of the
model.7,13 Our model does not include a calculator, which
is a relative limitation, since the score is calculated only
with five variables.
The most important strength of the PREDICE study is
the homogeneity of the cohorts used to develop and vali-
date the score in which only hospitalized patients with
new-onset HF are included. We excluded patients with a
previous diagnosis of HF to delimit the incident cases so
our model is very exclusive. It is known that “de novo” HF
and acute decompensating of chronic HF are different
entities so the models are not interchangeable.34 In fact,
multiple studies have found that acute decompensations of
chronic HF are more frequent while mortality in “de novo”
HF is higher.5,25 All this implies that it is not possible to
validate others’ models within our population because
another prognostic models refers to patients with chronic
HF. After initiating this study, another clinical prediction
rule in HF was published called AHEAD but it refers to
patients with chronic HF too, so we cannot use it to
validate our model. This study includes patients from
two European registries with first hospitalization for HF
where we also found patients with “de novo” HF and
patients with chronic HF decompensation.13
The study’s main limitation could be its sample size.
Only 180 were included, less than recommended in vali-
dation studies,16,35 although, prior to the study, a sample
size calculation was performed. Differentiating HF in sys-
tolic or diastolic is another limitation of our study, since
the model could have been used as a numerical variable.
Additionally, the last guidelines of ESC show HF with
a moderately reduced ejection fraction, although this is not
well established.1 In our study, we do not contemplate that
entity but it should be taken into account for future studies.
The population of validation cohort is recruited in the
same geographical and care areas as the development
cohort, but ten years later, which increases the transport-
ability. In addition, transportability increases if it is
another investigator group that carries out the validation.16
It is important to note the difference between HF with a
reduced ejection fraction (HFrEF) and HF with preserved
ejection fraction (HFpEF). The prevalence of HFpEF has
increased in western societies over recent years. The med-
ical knowledge is poor and no specific treatments have
been shown to reduce mortality. There are only expert
opinions for the management of this pathology.1,36 Both
in the development population and in the validation popu-
lation, the incidence of HFpEF is more frequent than
HFrEF,12 which is similar to findings in the literature.
This is a strength versus other predictive models for HF,
which included populations with similar incidences
between HFrEF and HFpEF.37
Some recent prognostic models include atrial fibrilla-
tion (AF) as a variable with predictive power,12 but other
earlier models do not include this variable.37 The preva-
lence of AF collected during the development and valida-
tion phases is around 30% similar to that found in other
studies. However, in the original article AF was not
included in the PREDICE prognostic model because it
didn’t reach sufficient predictive power.12 Given the high
prevalence of AF, it could be a limitation compared to
other studies.
Ruiz-Ruiz et al Dovepress
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In our study, the results are reported after a one-year
follow-up. This can be considered a limitation because in
one year new clinical situations may appear and these may
modify the course of the disease. On the other hand, this
can also be considered as strength, because it has a long-
term forecast although there are some articles that carry
out a longer follow-up of patients, up to five years.13 A
longer follow-up allows us to know more outcomes of the
same pathology, which can be valuable information.
Models that predict mortality in HF underestimate risk
in elderly patients.9,37 We have verified that our model
underestimates risk in elderly patients too because both
populations were elderly.12
Another choice when studying prognostic models lies
in the moment where the prognosis is to be estimated. If an
estimate is produced with data from the first evaluation,
information about early evolution is neglected, probably
losing accuracy but gaining interest (clinicians usually
want to estimate risk as early as possible). We produced
a prediction score which needs a physiopathology diagno-
sis by echocardiography and which does therefore not
allow for the earliest risk assessment, but does not need
to wait for a therapy response.
Conclusion
The present study shows that the two risk scores available
for patients with primo-hospitalization for decompensated
HF (PREDICE and AHEAD) are currently not valid for
predicting mortality at one year. Both models performed
poorly in the validation cohort compared to the develop-
ment cohort.
In our setting the clinical spectrum of hospitalized
patients with new-onset HF has been modified over time.
In the last decade there has been an increase in the average
age, comorbidities and dependence of patients, partly
because hospital admission criteria have become more
restrictive, which determines a worsening of their cardiac
and general functional situation and, consequently, of the
prognosis of the disease after hospitalization. The prog-
nosis of “de novo” HF remains uncertain. For this reason,
more research is needed to develop more accurate prog-
nosis rules to be able to identify high-risk patients who
require closer control and follow up.
The study underscores the need to validate the prog-
nostic models before clinical implementation. Prognostic
models developed should not be used if they are not
validated, especially if the target population differs from
the development one.
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